243 related articles for article (PubMed ID: 31377718)
21. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma.
Lee A; Duggan S; Deeks ED
Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208
[TBL] [Abstract][Full Text] [Related]
22. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
Kacew AJ; Harris EJ; Lorch JH; Haddad RI; Chau NG; Rabinowits G; LeBoeuf NR; Schmults CD; Thakuria M; MacConaill LE; Hanna GJ
Eur J Cancer; 2019 May; 113():1-9. PubMed ID: 30954880
[TBL] [Abstract][Full Text] [Related]
23. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios.
Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A
J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984
[TBL] [Abstract][Full Text] [Related]
24. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
25. GQ1b-Seronegative Miller Fisher Syndrome Associated With Pembrolizumab.
Green KE; Levine AM; Ward JH; Kaufman DI
J Neuroophthalmol; 2019 Sep; 39(3):394-396. PubMed ID: 30801443
[No Abstract] [Full Text] [Related]
26. Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.
Ma WL; Chou CH; Chen JP; Kuo SH
Dermatol Ther; 2020 Nov; 33(6):e14035. PubMed ID: 32683791
[TBL] [Abstract][Full Text] [Related]
27. [Cutaneous squamous cell carcinoma].
Leiter U; Gutzmer R; Alter M; Ulrich C; Meiwes A; Heppt MV; Steeb T; Berking C; Lonsdorf AS; Sachse MM; Garbe C; Hillen U
Hautarzt; 2020 Aug; 71(8):597-606. PubMed ID: 32583034
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
Hahn AW; Chahoud J; Campbell MT; Karp DD; Wang J; Stephen B; Tu SM; Pettaway CA; Naing A
Invest New Drugs; 2021 Oct; 39(5):1405-1410. PubMed ID: 33770291
[TBL] [Abstract][Full Text] [Related]
29. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma.
Hanania HL; Lewis DJ
Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605
[No Abstract] [Full Text] [Related]
30. Cemiplimab: First Global Approval.
Markham A; Duggan S
Drugs; 2018 Nov; 78(17):1841-1846. PubMed ID: 30456447
[TBL] [Abstract][Full Text] [Related]
31. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
Chen L; Aria AB; Silapunt S; Migden MR
Dermatol Surg; 2019 Jan; 45(1):1-16. PubMed ID: 30045105
[TBL] [Abstract][Full Text] [Related]
32. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
[No Abstract] [Full Text] [Related]
33. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report.
Nelson R; Luu L; Silberstein P; Velagapudi M; Huerter C
Int J Dermatol; 2021 Feb; 60(2):233-235. PubMed ID: 32955136
[No Abstract] [Full Text] [Related]
34. Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation.
Ali SA; Arman HE; Patel AA; Birhiray RE
JCO Oncol Pract; 2020 Mar; 16(3):137-138. PubMed ID: 31770056
[No Abstract] [Full Text] [Related]
35. Case Report: Cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy.
Sernicola A; Lampitelli S; Marraffa F; Maddalena P; Grassi S; Richetta AG; Calvieri S
F1000Res; 2019; 8():933. PubMed ID: 32047600
[TBL] [Abstract][Full Text] [Related]
36. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
38. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
39. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
[No Abstract] [Full Text] [Related]
40. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Ott PA; Piha-Paul SA; Munster P; Pishvaian MJ; van Brummelen EMJ; Cohen RB; Gomez-Roca C; Ejadi S; Stein M; Chan E; Simonelli M; Morosky A; Saraf S; Emancipator K; Koshiji M; Bennouna J
Ann Oncol; 2017 May; 28(5):1036-1041. PubMed ID: 28453692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
